First Time Loading...
R

Rallybio Corp
NASDAQ:RLYB

Watchlist Manager
Rallybio Corp
NASDAQ:RLYB
Watchlist
Price: 1.63 USD -1.21%
Updated: Apr 26, 2024

Intrinsic Value

RLYB's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. [ Read More ]

The intrinsic value of one RLYB stock under the Base Case scenario is 2.91 USD. Compared to the current market price of 1.63 USD, Rallybio Corp is Undervalued by 44%.

Key Points:
RLYB Intrinsic Value
Base Case
2.91 USD
Undervaluation 44%
Intrinsic Value
Price
R
Worst Case
Base Case
Best Case

Valuation Backtest
Rallybio Corp

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling RLYB stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Rallybio Corp

Provide an overview of the primary business activities
of Rallybio Corp.

What unique competitive advantages
does Rallybio Corp hold over its rivals?

What risks and challenges
does Rallybio Corp face in the near future?

Has there been any significant insider trading activity
in Rallybio Corp recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Rallybio Corp.

Provide P/S
for Rallybio Corp.

Provide P/E
for Rallybio Corp.

Provide P/OCF
for Rallybio Corp.

Provide P/FCFE
for Rallybio Corp.

Provide P/B
for Rallybio Corp.

Provide EV/S
for Rallybio Corp.

Provide EV/GP
for Rallybio Corp.

Provide EV/EBITDA
for Rallybio Corp.

Provide EV/EBIT
for Rallybio Corp.

Provide EV/OCF
for Rallybio Corp.

Provide EV/FCFF
for Rallybio Corp.

Provide EV/IC
for Rallybio Corp.

Show me price targets
for Rallybio Corp made by professional analysts.

What are the Revenue projections
for Rallybio Corp?

How accurate were the past Revenue estimates
for Rallybio Corp?

What are the Net Income projections
for Rallybio Corp?

How accurate were the past Net Income estimates
for Rallybio Corp?

What are the EPS projections
for Rallybio Corp?

How accurate were the past EPS estimates
for Rallybio Corp?

What are the EBIT projections
for Rallybio Corp?

How accurate were the past EBIT estimates
for Rallybio Corp?

Compare the revenue forecasts
for Rallybio Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Rallybio Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Rallybio Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of Rallybio Corp compared to its peers.

Compare the P/E ratios
of Rallybio Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing Rallybio Corp with its peers.

Analyze the financial leverage
of Rallybio Corp compared to its main competitors.

Show all profitability ratios
for Rallybio Corp.

Provide ROE
for Rallybio Corp.

Provide ROA
for Rallybio Corp.

Provide ROIC
for Rallybio Corp.

Provide ROCE
for Rallybio Corp.

Provide Gross Margin
for Rallybio Corp.

Provide Operating Margin
for Rallybio Corp.

Provide Net Margin
for Rallybio Corp.

Provide FCF Margin
for Rallybio Corp.

Show all solvency ratios
for Rallybio Corp.

Provide D/E Ratio
for Rallybio Corp.

Provide D/A Ratio
for Rallybio Corp.

Provide Interest Coverage Ratio
for Rallybio Corp.

Provide Altman Z-Score Ratio
for Rallybio Corp.

Provide Quick Ratio
for Rallybio Corp.

Provide Current Ratio
for Rallybio Corp.

Provide Cash Ratio
for Rallybio Corp.

What is the historical Revenue growth
over the last 5 years for Rallybio Corp?

What is the historical Net Income growth
over the last 5 years for Rallybio Corp?

What is the current Free Cash Flow
of Rallybio Corp?

Discuss the annual earnings per share (EPS)
trend over the past five years for Rallybio Corp.

Financials

Balance Sheet Decomposition
Rallybio Corp

Current Assets 114.8m
Cash & Short-Term Investments 109.9m
Other Current Assets 4.9m
Non-Current Assets 831k
Long-Term Investments 239k
PP&E 592k
Current Liabilities 9.3m
Accounts Payable 976k
Accrued Liabilities 8.3m
Non-Current Liabilities 173k
Other Non-Current Liabilities 173k
Efficiency

Earnings Waterfall
Rallybio Corp

Revenue
0 USD
Operating Expenses
-78.9m USD
Operating Income
-78.9m USD
Other Expenses
4.4m USD
Net Income
-74.6m USD

Free Cash Flow Analysis
Rallybio Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

RLYB Profitability Score
Profitability Due Diligence

Rallybio Corp's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

Rallybio Corp's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

RLYB Solvency Score
Solvency Due Diligence

Rallybio Corp's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
63/100
Solvency
Score

Rallybio Corp's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RLYB Price Targets Summary
Rallybio Corp

Wall Street analysts forecast RLYB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RLYB is 12.6 USD .

Lowest
Price Target
Not Available
Average
Price Target
12.6 USD
673% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

RLYB Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

RLYB Price
Rallybio Corp

1M 1M
+11%
6M 6M
-57%
1Y 1Y
-70%
3Y 3Y
-88%
5Y 5Y
-88%
10Y 10Y
-88%
Annual Price Range
1.63
52w Low
1.25
52w High
8.89
Price Metrics
Average Annual Return -33.38%
Standard Deviation of Annual Returns 9.89%
Max Drawdown -95%
Shares Statistics
Market Capitalization 61.7m USD
Shares Outstanding 37 812 000
Percentage of Shares Shorted 4.12%

RLYB Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Rallybio Corp

Country

United States of America

Industry

Biotechnology

Market Cap

61.7m USD

Dividend Yield

0%

Description

Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. The company is headquartered in New Haven, Connecticut and currently employs 35 full-time employees. The company went IPO on 2021-07-29. The firm is engaged in discovering, developing, manufacturing and delivering therapies that improve the lives of patients suffering from severe and rare diseases. The company offers a program for the prevention of fetal and neonatal alloimmune thrombocytopenia, a rare hematological disease that impacts fetuses and newborns. The company provides RLYB211, a polyclonal anti-HPA-1a antibody. Its RLYB211 is in Phase I/II clinical trial. The Company’s lead product candidate, RLYB212, is a monoclonal anti-HPA-1a antibody. The company is also focused on developing therapies that address diseases of complement dysregulation, including paroxysmal nocturnal hemoglobinuria (PNH), generalized myasthenia gravis (gMG), and ophthalmic disorders. Its RLYB116 is a long-acting, subcutaneously administered inhibitor of complement factor 5 (C5) in development for the treatment of patients with PNH and gMG. The company also includes RLYB114, which is a pegylated C5 inhibitor.

Contact

CONNECTICUT
New Haven
234 Church Street, Suite 1020
+12038593820.0
https://rallybio.com/

IPO

2021-07-29

Employees

35

Officers

Co-Founder & Executive Chairman
Dr. Martin W. MacKay Ph.D.
Co-Founder, President, CEO & Director
Dr. Stephen Uden M.B, M.D.
CFO & Treasurer
Mr. Jonathan I. Lieber M.B.A.
Head of Investor Relations & Corporate Communications
Ms. Ami Bavishi
Chief Medical Officer
Dr. Steven W. Ryder F.A.C.P, M.D.

See Also

Discover More
What is the Intrinsic Value of one RLYB stock?

The intrinsic value of one RLYB stock under the Base Case scenario is 2.91 USD.

Is RLYB stock undervalued or overvalued?

Compared to the current market price of 1.63 USD, Rallybio Corp is Undervalued by 44%.